Incyte Corporation (INCY)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $24.66B
Last updated: Nov 17, 2026 at 11:06 AM ET
Incyte Corporation (INCY) Stock Forecast
Analysts expect Incyte (INCY) to earn $3.46 per share in the fiscal year ending Dec 31, 2026, on revenue of $6.05B. Of 28 analysts, 13 rate the stock Buy or Strong Buy, 14 Hold and 1 Sell or Strong Sell, for a consensus of Hold. Over the last 30 days, 6 estimates for the fiscal year ending Dec 31, 2026 were revised up and 3 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 28 ratings average 2.50, inside the Hold band from 2.5 up to 3.5. Buy and Strong Buy make up 46% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 2 | 7.1% |
| Buy | 11 | 39.3% |
| Hold | 14 | 50.0% |
| Sell | 1 | 3.6% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Hold
- Total analysts
- 28
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 149.7% and revenue estimates rise 4.3%.
- Fiscal year ending Dec 31, 2026
- $3.46
- EPS consensus, revenue $6.05B
- Fiscal year ending Dec 31, 2027
- $8.64
- EPS consensus, revenue $6.31B
- Next report
- Feb 8, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $3.46 | $2.76 to $4.38 | 19 | $6.05B | $5.96B to $6.11B | 21 |
| Dec 31, 2027 | $8.64 | $6.19 to $9.95 | 22 | $6.31B | $6.01B to $6.79B | 23 |
Quarterly Estimates
The EPS consensus falls from $2.03 for the quarter ending Dec 31, 2026 to $1.72 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $2.03 | $1.56 to $3.23 | 26 | $1.58B | $1.46B to $1.69B | 24 |
| Mar 31, 2027 | $1.72 | $1.15 to $1.95 | 7 | $1.36B | $1.33B to $1.40B | 8 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 11 upward and 18 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 6 | 3 |
| Fiscal year ending Dec 31, 2027 | 5 | 12 |
| Quarter ending Mar 31, 2027 | 0 | 3 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has fallen 3.1% from $3.57.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $3.46 | $3.49 | $3.31 | $3.48 | $3.57 | -3.2% |
| Fiscal year ending Dec 31, 2027 | $8.64 | $8.77 | $8.70 | $8.83 | $8.82 | -2.0% |
| Quarter ending Mar 31, 2027 | $1.72 | $1.78 | $1.73 | $1.76 | $1.74 | -1.5% |
Frequently Asked Questions About INCY
What is the INCY stock forecast?
Consensus analyst estimates put Incyte's EPS at $3.46 for the fiscal year ending Dec 31, 2026, on revenue of $6.05B. The consensus rating from 28 analysts is Hold.
How do analysts rate INCY stock?
Of 28 analysts covering Incyte, 2 rate it Strong Buy, 11 Buy, 14 Hold, 1 Sell and 0 Strong Sell, for a consensus of Hold.
What EPS do analysts expect from INCY next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $3.46, with estimates from $2.76 to $4.38 from 19 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $8.64, with estimates from $6.19 to $9.95 from 22 analysts.
What revenue do analysts expect from Incyte next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $6.05B, with estimates from $5.96B to $6.11B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $6.31B, with estimates from $6.01B to $6.79B.
How many analysts cover INCY?
28 analysts rate Incyte stock, and 19 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
INCY pages: Overview, Earnings, Forecast, Financials, Valuation